Though osimertinib is the preferred first-line option for advanced EGFR-mutated NSCLC, its high cost previously hindered its cost-effectiveness as a first-line treatment in many countries [73–77]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.